Analysis of Curative Effect of Dapagliflozin Combined with Sacubitril/Valsartan on Cardiac Function in Patients with Heart Failure
Objective To investigate the effects of Dapagliflozin combined with Sacubitril/Valsartan on cardiac function and prognosis in patients with ischemia-reperfusion heart failure.Methods A total of 100 patients with acute myocardial infarction ische-mia-reperfusion heart failure who were hospitalized in the Department of Cardiology of the Third Affiliated Hospital of Jinzhou Medical University from October 2020 to September 2022 were selected and divided into observation group(n=50)and control group(n=50)by random number table method.The medical records of the patients were collected.On the basis of routine treatment,the ob-servation group was treated with Dapagliflozin combined with Sacubitril/Valsartan,and the control group was treated with Sacubitril/Valsartan.After 6 months of treatment,serum creatinine(Scr)and serum cystatin C(Cys-C)were compared within groups and between the two groups,and renal function was evaluated.B-type natriuretic peptide(BNP),echocardiography[left ventricular end diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF)and left atrial diastolic diameter(LAD)]were compared within groups and between the two groups to evaluate the cardiac function of the two groups.Intra-group and inter-group KCCQ scores were compared to assess patients'quality of life.The 6-minute walking test(6MWT)and assessment NYHA cardiac function classifi-cation were performed on 1 month after discharge and 6 months after treatment to compare exercise capacity and clinical efficacy of pa-tients within and between the two groups.Outpatients were followed up for 6 months,and major adverse cardiovascular events(MACE)(including heart failure readmission and cardiovascular death)were recorded.Results Clinical efficacy was compared:After treatment,the total effective rate of the observation group was 97.80％,which was significantly higher than that of the control group(87.00％),and the difference was statistically significant(P<0.05);after treatment,the cardiac function level(LVEF,LVEDD,BNP,6MWD),renal function(Cys-C,Scr)and quality of life(KCCQ score)in observation group were better than those in control group,and the difference was statistically significant(P<0.05).Conclusion Dapagliflozin combined with Sacubi-tril/Valsartan can significantly improve the clinical symptoms and cardiac function of patients with ischemia-reperfusion,improve the living quality of patients,reduce the incidence of adverse cardiovascular events,and improve the clinical prognosis.
NETL
NSTL
万方数据
